TICKERNOMICS Sign up
Last Update: 2023-10-04 11:36:14
Cortexyme Inc ( CRTX ) https://www.cortexyme.com
1.33USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
14.73%
CRTX
0.00%
SPY
36.71%
-97.31%
CRTX
SPY
70.96%
CRTX
0.00%
SPY
262.36%
CRTX
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
48.25
-18.96
0.13
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-1.14
23.69
0.53
-129.23
0.00
0.42
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-1845.58
0.00
-1584.36
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
8.7613
-83.13
-47.15
1.23
Other Earnings and Cash Flow Stats:
Cortexyme Inc ( CRTX ) Net Income TTM ($MM) is -58.38
Cortexyme Inc ( CRTX ) Operating Income TTM ($MM) is -58.70
Cortexyme Inc ( CRTX ) Owners' Earnings Annual ($MM) is -49.81
Cortexyme Inc ( CRTX ) Current Price to Owners' Earnings ratio is -0.97
Cortexyme Inc ( CRTX ) EBITDA TTM ($MM) is -58.42
Cortexyme Inc ( CRTX ) EBITDA Margin is -1584.36%
Capital Allocation:
Cortexyme Inc ( CRTX ) has paid 0.00 dividends per share and bought back -0.148127 million shares in the past 12 months
Cortexyme Inc ( CRTX ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
Cortexyme Inc ( CRTX ) Interest-bearing Debt ($MM) as of last quarter is 0
Cortexyme Inc ( CRTX ) Annual Working Capital Investments ($MM) are -2
Cortexyme Inc ( CRTX ) Book Value ($MM) as of last quarter is 90
Cortexyme Inc ( CRTX ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
Cortexyme Inc ( CRTX ) has 42 million in cash on hand as of last quarter
Cortexyme Inc ( CRTX ) has 3 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Cortexyme Inc ( CRTX ) has 36 common shares outstanding as of last quarter
Cortexyme Inc ( CRTX ) has 0 million USD of preferred stock value
Academic Scores:
Cortexyme Inc ( CRTX ) Altman Z-Score is 4.37 as of last quarter
Cortexyme Inc ( CRTX ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
Cortexyme Inc ( CRTX ) largest shareholder is Renaissance Technologies Corp owning 279499 shares at 0.37 ($MM) value
Caryn Gordon Mcdowell(an insider) Sold 10800 shares of Cortexyme Inc ( CRTX ) for the amount of $30888.00 on 2022-06-06
24.50% of Cortexyme Inc ( CRTX ) is held by insiders, and 40.47% is held by institutions
Cortexyme Inc ( CRTX ) went public on 2019-05-09
Other Cortexyme Inc ( CRTX ) financial metrics:
FCF:-50.64
Unlevered Free Cash Flow:-35.00
EPS:-1.36
Operating Margin:-1845.58
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-54.34
Beta:1.23
Buffet's Owners Earnings:-49.81
Price to Owner's Earnings:-0.97
About Cortexyme Inc ( CRTX ) :
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.